[Asia Economy Reporter Junho Hwang] VigenCell announced on the 23rd that it has submitted an Investigational New Drug (IND) application for the Phase 1 clinical trial of VT-Tri(2), a treatment for recurrent glioblastoma, to the Ministry of Food and Drug Safety.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
